Should we be concerned about the SARS-CoV-2 Lambda variant?

As the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wreaks havoc across the globe, the efficacy of available vaccines is being threatened by emerging variants.

Several new variants have been identified, which may cause severe illness in some people and are more transmissible. The World Health Organization (WHO) recently classified the lambda variant as a " Variant of Interest."

The WHO describes a Variant of Interest (VOI) as having genetic changes predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape.

In a report posted to the pre-print server medRxiv, researchers recently discussed the emergence of a novel lineage of SARS-CoV-2 in South America.

Transmission electron micrograph of SARS-CoV-2 virus particles. Image Credit: NIAID
Transmission electron micrograph of SARS-CoV-2 virus particles. Image Credit: NIAID

Where did the lambda variant come from?

First detected in Lima, Peru, in December 2020, the variant accounted for 97% of all sequences in Peru by April 2021. The variant has spread to neighboring countries like Chile, Argentina, Colombia, Ecuador, Mexico, the United States, Israel, Germany, and even Australia.

The most concerning news about the lambda variant is it has dominated new infections in Peru, a country with the highest number of COVID-19 deaths per capita. For every 100,000 of the country's population, 596 have died of the infection. Overall, Peru has lost nearly 195,000 people to COVID-19 among its population of over 32 million, which is about three times the rate of U.S. deaths per capita.

With more than 2 million reported infections to date, Peru has been hit by the coronavirus pandemic. The country continues to fight the global health crisis despite a limited healthcare capacity, a slow vaccine rollout, and outdated intensive care units (ICUs).

Because of these factors, the lambda variant spread throughout the country and other regions—the WHO reported that the variant had been detected in 29 countries with increasing prevalence.

Lambda characteristics

Like other variants, the lambda variant has mutations that increase transmissibility. In addition, evidence suggests that the variant affects how fast the infection spreads, the severity of the illness, and the ability to evade immunity to natural infection or vaccination.

Also called the C.37 variant, it presents with seven nonsynonymous mutations in the Spike (S) gene, including G75V, T76I, D614G, L452Q, F490S, T859N. In addition, the variant has a deletion in the ORF1a gene, Δ3675-3677, which is also found in other variants of concern (VOCs) Alpha, Beta, and Gamma.

The mutations L452Q and F490S map to the Spike protein's receptor-binding domain (RBD), the part of the coronavirus that binds to the human angiotensin-converting enzyme 2 (hACE 2) receptor to invade the cells. Though L452Q is almost exclusive to C.37, L452R is present in the currently dreaded B.1.617.2 or Delta variant, and the variants of interest Epsilon (B.1.427/B.1.429) and Kappa (B.1.617.1).  The L452R is also linked to reduced in vitro susceptibility to antibody neutralization.

These mutations within the RBD may contribute to its increased transmissibility and could result in susceptibility to re-infection or a reduction in the protection provided by current vaccines.

Since the lambda variant is novel, there is limited data on how it can affect the current pandemic trends. A study that appeared in the pre-print server bioRxiv showed how the lambda spike protein contains novel mutations within the RBD that increase transmissibility.

When the researchers examined the infectivity and susceptibility of viruses with the lambda variant spike protein to neutralization by vaccine-induced antibodies or convalescent sera, they revealed that the lambda variant exhibited higher infectivity and was neutralized with a moderately minor 2.3 to 3.3-fold decrease in titer. This means that the current vaccines and convalescent sera are potentially effective in protecting against this VOC.

Global situation

To date, there are over 188 million cases of COVID-19 since it first emerged in December 2020. Of these, more than 4 million people have already died. The United States reports the highest COVID-19 cases, topping 33.94 million cases, followed by India and Brazil, with 30.94 million and 19.2 million cases, respectively.​

Sources:
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2021, July 15). Should we be concerned about the SARS-CoV-2 Lambda variant?. News-Medical. Retrieved on July 25, 2021 from https://www.news-medical.net/news/20210715/Should-we-be-concerned-about-the-SARS-CoV-2-Lambda-variant.aspx.

  • MLA

    Laguipo, Angela. "Should we be concerned about the SARS-CoV-2 Lambda variant?". News-Medical. 25 July 2021. <https://www.news-medical.net/news/20210715/Should-we-be-concerned-about-the-SARS-CoV-2-Lambda-variant.aspx>.

  • Chicago

    Laguipo, Angela. "Should we be concerned about the SARS-CoV-2 Lambda variant?". News-Medical. https://www.news-medical.net/news/20210715/Should-we-be-concerned-about-the-SARS-CoV-2-Lambda-variant.aspx. (accessed July 25, 2021).

  • Harvard

    Laguipo, Angela. 2021. Should we be concerned about the SARS-CoV-2 Lambda variant?. News-Medical, viewed 25 July 2021, https://www.news-medical.net/news/20210715/Should-we-be-concerned-about-the-SARS-CoV-2-Lambda-variant.aspx.

Comments

  1. MOSS MONACO MOSS MONACO United Kingdom says:

    Attributable to further mutation?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission